Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6352W HIGH $3.78
Volume
206.41 K
Value Traded
141.02 K
Short % Float
6.59%
Days to Cover
10.3
-1.21%Week
-22.31%1 Month
-51.12%3 Month
-79.97%6 Month
-85.15%5 Year
-99.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.88 M
EPS (TTM)
-0.56
P/E Ratio
-
Ent. Value
265.65 K
Total Shares
19.67 M
Float Shares
17.36 M
Insiders
11.72%
Institutions
12.27%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
DARE Catalyst Timeline
Dated clinical, regulatory and corporate events for Dare Bioscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dare Bioscience, Inc.
369Total events
15Upcoming
100Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Grant / FundingDARE-LARC1Corporate
Daré received $1.5M grant installment for DARE-LARC1, bringing total to ~$43.3M
contraceptionsource ↗
◆Poster PresentationSildenafilPresentation
Planned poster presentation of Phase 1 data for Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Society 2026 Annual Meeting
postmenopausal women (sexual health)source ↗
●Poster PresentationSildenafilPresentation
Phase 1 Sildenafil Cream data presented at SMSNA Annual Fall Scientific Meeting
healthy male adultssource ↗
●R&D DayPresentation
Management on-site for one-on-one investor meetings at H.C. Wainwright 28th Annual Global Investment Conference
▲PublicationSildenafilPresentation
Peer-reviewed publication in Sexual Medicine of Phase 1 topical Sildenafil Cream study in healthy men
systemic pharmacokinetics and safety in healthy adult mensource ↗
▲PK PD DataSildenafilClinical Data
Phase 1 topical Sildenafil Cream showed ~187-fold lower mean Cmax at 71 mg vs 50 mg oral sildenafil
systemic pharmacokinetics in healthy adult mensource ↗
▲Safety Data UpdateSildenafilClinical Data
Phase 1 study reported all 14 TEAEs mild, no serious AEs or discontinuations
safety in healthy adult mensource ↗
●R&D DayPresentation
Daré Bioscience pre-recorded presentation available on-demand for H.C. Wainwright 28th Annual Global Investment Conference
▲Preclinical PoCDARE-PTB2Preclinical
NIH funding award for preclinical development of DARE-PTB2
preterm birthsource ↗
▲PublicationSildenafilPresentation
Sildenafil Cream data published in Menopause journal
postmenopausal womensource ↗
◆Equity OfferingCorporate
Closing of registered direct offering and concurrent private placement
▲Patent GrantedDARE-HPVIP / Competition
U.S. Patent No. 12,678,439 issued covering lopinavir/ritonavir topical compositions for HPV-related cervical pathologies
HPV-related cervical pathologiessource ↗
▲Product LaunchSildenafilPost-Market
Progressing toward national dispensing and initial revenue
▲Trial InitiationDARE-HPVTrial
Initiation of Phase 2 clinical study of DARE-HPV
persistent high-risk HPV infectionsource ↗
▲Product LaunchPost-Market
Flora Sync LF5 expected to become commercially available through DARE Health Hub
vaginal microbiome balancesource ↗
◆Quarterly UpdateCorporate
Full Year 2025 Financial Results and Company Update Conference Call
▲Product LaunchPost-Market
Commercial launch of DARE to PLAY Sildenafil Cream as 503B compounded product
female sexual arousal disordersource ↗
▲Product LaunchSildenafilPost-Market
DARE to PLAY™ Sildenafil Cream available as Section 503B compounded product
female sexual arousalsource ↗
▲IND ClearanceDARE-HPVIND
FDA clearance of IND for DARE-HPV
high-risk human papillomavirus (HPV) infectionsource ↗
▲IND ClearanceDARE-HPVIND
FDA cleared IND for DARE-HPV Phase 2 study
persistent high-risk HPV infectionsource ↗
▲Product LaunchSildenafilPost-Market
Telehealth consultations for DARE to PLAY™ Sildenafil Cream now available nationwide
female sexual arousalsource ↗
◆Partnership / LicenseOvapreneCorporate
Bayer terminates license agreement for Ovaprene; rights to return to Dare
contraceptionsource ↗
▲IND ClearanceDARE-HPVIND
FDA cleared IND application for DARE-HPV
persistent high-risk HPV infectionsource ↗
▲Product LaunchDARE-HRT1Post-Market
Targeting availability as a Section 503B compounded drug next year
vasomotor symptoms of menopausesource ↗
▲Product LaunchPost-Market
Targeted availability of DARE to RESTORE vaginal probiotics
vaginal microbiome healthsource ↗
▲Product LaunchSildenafilPost-Market
DARE to PLAY Sildenafil Cream available for pre-order by prescription in select states via 503B outsourcing facility
female sexual arousalsource ↗
▲Product LaunchSildenafilPost-Market
Initial prescription fulfillment for DARE to PLAY Sildenafil Cream via 503B pathway
women's sexual healthsource ↗
◆Oral PresentationSildenafilPresentation
Webinar on DARE to PLAY difference with clinicians
female sexual arousal disordersource ↗
▲Milestone PaymentDARE-NHCCorporate
Anticipated grant installment for DARE-NHC
non-hormonal contraceptionsource ↗
◆Product LaunchSildenafilPost-Market
Targeted availability by prescription in the US as a compounded drug under Section 503B
female sexual arousal disordersource ↗
▲Product LaunchPost-Market
DARE to PLAY sildenafil cream expected to be available by prescription
female sexual arousal disordersource ↗
◆Product LaunchSildenafilPost-Market
Anticipated launch of DARE to PLAY Sildenafil Cream via 503B compounding pathway
female sexual arousal disordersource ↗
▲Milestone PaymentDARE-LARC1Corporate
Grant installment received for DARE-LARC1
long-acting contraceptionsource ↗
▲Product LaunchSildenafilPost-Market
Sildenafil Cream available via 503B compounding in Q4 2025
female sexual arousal disordersource ↗
▲Partnership / LicenseCorporate
Gates Foundation agreement for mentorship and project management support for preeclampsia research
preeclampsiasource ↗
▲DSMB ReviewOvapreneTrial
Positive interim DSMB outcome for Ovaprene Phase 3 study supports continued enrollment
contraceptionsource ↗
◆Oral PresentationPresentation
Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar
female sexual arousal disordersource ↗
▲Interim AnalysisOvapreneTrial
Positive interim safety and efficacy results from Phase 3 trial of Ovaprene
contraceptionsource ↗
●Enrollment UpdateOvapreneTrial
Approximately 115 participants ongoing or completed; target enrollment ~250
contraceptionsource ↗
Past FDA Catalysts and PDUFA Decisions
How DARE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-30 | DARE-IDDS | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 68%
Micro Cap(rank 459 of 674)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026)
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DARE-HPV Small moleculeNCT07601074 | Human Papilloma Virus (HPV) | Phase 2 | RECRUITING | 118 | Dec 1, 2027 | ||||||
| Progesterone Small moleculeNCT06668896 | Pre Term Birth | Phase 1 | NOT YET_RECRUITING | 60 | Apr 1, 2028 | ||||||
| Diclofenac 1% Small moleculeCompletedNCT05752526 | Dysmenorrhea Primary | Phase 1 | COMPLETED | 42 | Apr 26, 2024 | ||||||
| Sildenafil Small moleculeCompletedNCT05765487 | Sexual Arousal Disorder | Phase 1 | COMPLETED | 13 | Oct 21, 2024 | ||||||
| DARE-BV1 Small moleculeCompletedNCT05354050 | Bacterial Vaginosis | Phase 1 | COMPLETED | 21 | Dec 2, 2020 | ||||||
| IVR Dose 1, IVR Dose 2 UnknownCompletedNCT05367973 | Vulvovaginal Atrophy | Phase 1/2 | COMPLETED | 55 | Mar 23, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every DARE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Sildenafil Cream | female sexual arousal disorder | Phase 1 | 2026-10-08 | mean maximum plasma concentration: approximately 187-fold lower; systemic exposure AUC: approximately 33- to 34-fold lower; adverse events: All treatment-emergent adverse events reported in the study were mild, with no serious adverse eventsRead More | Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Grossman Jessica D.Director | Grant/Award | 26,066 26,066 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DARE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DARE for Q2 2026. | ||||
Ownership Trends
DARE Short Interest
Shares sold short, counted twice a month.
6.59%
Short % of Float
of tradable shares sold short
1.1M
Shares Sold Short
+24.0% vs prior count
10.3 Very high
Days to Cover
trading days of normal volume to buy every short share back
111.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DARE ranks across every disease it competes in
Competitive Position is a premium feature
See how DARE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDARE News
DAREDaré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Daré Bioscience announced a $1.5 million funding installment, bringing total non-dilutive funding to approximately $43.3 million for DARE-LARC1, a long-acting contraceptive. The company is advancing preclinical development and exploring strategic collaborations for its DARE-IDDS platform, which may extend to obesity and diabetes treatments. CEO Sabrina Martucci Johnson emphasized the importance of this funding for women's health solutions.
Read more →DAREDaré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion
Daré Bioscience participated in a Virtual Investor segment discussing the recent Executive Order aimed at enhancing women's health. CEO Sabrina Martucci Johnson highlighted the significance of this initiative for companies addressing unmet needs in women's health. The company plans to advance its commercial strategy, including the upcoming prescription dispensing of DARE to PLAY Sildenafil Cream.
Read more →DAREDaré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
Daré Bioscience will present its investigational device, DARE-IDDS, at the PODD 2026 conference. This device is designed to deliver over 100 doses wirelessly, addressing challenges in chronic therapies. It aims to improve patient adherence by reducing the need for frequent injections and clinic visits. The technology is initially targeted for contraception but may have broader applications.
Read more →DAREDaré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Daré Bioscience has announced its sponsorship of the HERmedicine program focused on managing menopause after breast cancer. This initiative aims to educate clinicians on non-hormonal treatment options for women facing menopausal symptoms due to breast cancer. The company will also present research on its Sildenafil Cream, 3.6% at The Menopause Society's 2026 Annual Meeting, highlighting its commitment to women's health.
Read more →DAREDaré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
Daré Bioscience has launched a new video series called 'CEO Corner,' featuring insights from CEO Sabrina Martucci Johnson. The series aims to provide investors with an understanding of the company's strategic priorities and its transition to a commercial-stage women's health company. Future episodes will cover various topics related to Daré's product portfolio and clinical development.
Read more →DAREDaré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
Daré Bioscience announced the presentation of Phase 1 study data for its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study demonstrated that the topical formulation resulted in significantly lower systemic exposure compared to oral sildenafil, with no serious adverse events reported. This data supports further development of the cream as a potential treatment for female sexual arousal disorder.
Read more →DAREDare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
Daré Bioscience has announced the issuance of a new U.S. patent for its DARE-HPV program, which aims to be the first FDA-approved pharmacologic treatment for high-risk HPV infection. The program is currently in Phase 2 clinical trials, with topline results anticipated in 2027. Supported by substantial funding, DARE-HPV targets a significant unmet medical need in women's health.
Read more →DAREDaré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Daré Bioscience announced the publication of a Phase 1 study on its topical Sildenafil Cream, showing it has significantly lower systemic exposure compared to oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and demonstrated the cream's safety and pharmacokinetics. Results indicate a promising approach for addressing sexual health concerns.
Read more →DAREDaré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
Daré Bioscience has made its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference available for on-demand viewing. The presentation, led by CEO Sabrina Martucci Johnson, covers the company's recent developments and future direction. The conference will take place from September 14-16, 2026, in New York, where management will meet with investors.
Read more →DAREDaré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
Daré Bioscience received a new award from the National Institutes of Health for approximately $908,000. This funding supports the preclinical development of DARE-PTB2, an investigational program aimed at preventing preterm birth. The notice also recommends future-year support of approximately $1.3 million for additional safety and toxicity studies. The company stated this non-dilutive grant advances its strategy to address unmet medical needs in women's health.
Read more →DAREDaré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Daré Bioscience announced that CEO Sabrina Martucci Johnson participated in the Virtual Investor “Why Now” on-demand series. She presented the company's investment thesis and highlighted its first direct product launch. The presentation also covered the firm's diversified pipeline and strategic collaboration-driven development approach. The video webcast is now available for on-demand viewing.
Read more →DARE▼ -8.5%on this newsshared move
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré Bioscience published Phase 1 data showing its topical sildenafil cream was well tolerated in postmenopausal women. The study enrolled 21 participants and found minimal systemic exposure at the 100 mg dose. Maximum plasma concentration reached approximately 3,810 pg/mL, which is two orders of magnitude lower than levels seen in men. The company plans to launch a compounded version in Q3 2026 while pursuing FDA approval.
Read more →DAREDaré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
Daré Bioscience reported positive interim Phase 3 results for Ovaprene. The company is transitioning to a commercial stage with the launch of Flora Sync LF5. It also prepares to generate revenue from DARE to PLAY Sildenafil Cream. These developments aim to drive value over the next 12 to 18 months.
Read more →DARE▼ -5.2%on this news
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
Daré Bioscience announced that CEO Sabrina Martucci Johnson was named to the Forbes 2026 “50 Over 50: Innovation” list. The company highlighted its diverse portfolio, which includes the FDA-approved XACIATO vaginal gel and the Phase 3 Ovaprene contraceptive program. Flora Sync LF5 also launched commercially in July 2026 to generate direct revenue. These developments support the firm’s strategy to expand beyond clinical-stage biotechnology into a multi-product women’s health business.
Read more →DARE▼ -35.4%on this newsshared move
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Daré Bioscience has announced a registered direct offering of 4,379,581 shares at $1.37 each, aiming to raise $6 million. The offering is set to close around August 17, 2026, subject to customary conditions. Additionally, the company will issue Series A and B warrants, pending stockholder approval. This move supports Daré's mission in women's health.
Read more →DARE▼ -32.1%on this newsshared move
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
Daré Bioscience reported second quarter 2026 revenue of $0.2 million, driven by research and development services. The company holds $12.6 million in cash and faces a working capital deficit of $0.2 million. Flora Sync LF5 launched as the first directly commercialized product, generating revenue starting in July. DARE to PLAY Sildenafil Cream is expected to begin prescription dispensing and generate initial revenue in the third quarter of 2026.
Read more →DAREDaré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
Daré Bioscience, Inc. will host a conference call on August 13, 2026, to discuss its financial results for Q2 2026 and provide a company update. The call will be accessible via phone and webcast, with registration recommended prior to the event. The company emphasizes its commitment to women's health through innovative solutions.
Read more →DARE▼ -10.2%on this news
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
Daré Bioscience announced a strategic collaboration with MyMenopauseRx to expand access to specialized menopause care for users of DARE to PLAY. The partnership features the telehealth platform as a dedicated partner for the company’s Sildenafil Cream. This move aims to broaden Daré’s commercial reach and strengthen consumer engagement within the women’s health sector. The initiative supports the company’s strategy to build a comprehensive ecosystem connecting products with clinical expertise.
Read more →DARE▼ -6.7%on this news
Press Release: Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
Daré Bioscience has announced the launch of its 'Across the U.S.' Virtual Bus Tour Webinar Series aimed at engaging investors. The series will feature presentations from CEO Sabrina Martucci Johnson, discussions on the company's women's health portfolio, and updates on business initiatives. Investors can register for multiple regional events, with replays available for later viewing.
Read more →DAREPress Release: Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Daré Bioscience will participate in a Virtual Investor Closing Bell event on July 14, 2026. CEO Sabrina Martucci Johnson will discuss the company's recent product launch, strategic growth plans, and capital allocation approach. The event will also include a live Q&A session for audience engagement. A webcast will be available for those unable to attend live.
Read more →About Dare Bioscience, Inc.
Headquarters3655 NOBEL DRIVE, SAN DIEGO, CA, 92122
BIOPHARMAWATCH ELITE PLUS
Trade the next DARE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime